Search results for "Cytotoxic"

showing 10 items of 1673 documents

High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells

2020

Multiple myeloma (MM) is characterized by aberrant bone marrow plasma cell (PC) proliferation and is one of the most common hematological malignancies. The potential effect of cannabinoids on the immune system and hematological malignancies has been poorly characterized. Cannabidiol (CBD) may be used to treat various diseases. CBD is known to exert immunomodulatory effects through the activation of cannabinoid receptor 2 (CB2), which is expressed in high levels in the hematopoietic system. Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T lymphocytes obtained via ex vivo sequential incubation of peripheral blood mononuclear cells (PBMCs) with interferon-&gam…

Cytotoxicity ImmunologicAdoptive cellular immunotherapyEndocannabinoid systemcytokine-induced killer cellsCD3Multiple myeloma.Plasma cellPeripheral blood mononuclear cellArticleCatalysisReceptor Cannabinoid CB2lcsh:ChemistryInorganic ChemistryImmune systemCell Line TumormedicineHumansCannabidiolCytotoxic T cellPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyCells CulturedSpectroscopyCytokine-induced killer cellbiologyChemistryOrganic ChemistryGeneral MedicineComputer Science Applicationsmultiple myelomaHaematopoiesisCytokine-induced killer cellmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Cancer researchbiology.proteinBone marrowInternational Journal of Molecular Sciences
researchProduct

Cellular cytotoxicity against autologous hepatocytes in alcoholic liver disease.

2008

We tested lymphocyte cytotoxicity against autologous hepatocytes in patients with alcoholic liver disease (ALD). The following cytotoxicity values were found (mean +/- SEM): alcohol-induced steatosis with or without fibrosis 16.5 +/- 2% (n = 29), alcoholic cirrhosis 28 +/- 4% (n = 13), controls with normal liver histology or minimal changes 6 +/- 2% (n = 11). The differences were statistically significant (both forms of ALD versus controls p less than 0.005). T-cell as well as non-T-cell-enriched lymphocyte fractions showed increased cytotoxicity in ALD. We did not observe a correlation between cellular cytotoxicity and the degree of biochemical or histological alterations within the groups…

Cytotoxicity ImmunologicAlcoholic liver diseasemedicine.medical_specialtyPathologyCirrhosisHepatologyLymphocyteHepatobiliary diseaseBiologyMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyLiverFibrosisLiver Cirrhosis AlcoholicHepatocyteInternal medicinemedicineHumansSteatosisCytotoxicityFatty Liver AlcoholicT-Lymphocytes CytotoxicLiver
researchProduct

Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy

2019

Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by e…

Cytotoxicity ImmunologicAllogeneic transplantationAdoptive cellular immunotherapyCD3CellPopulationReviewImmunotherapy AdoptiveDendritic cellsCatalysisInorganic Chemistrylcsh:ChemistryDendritic cells.medicineCytotoxic T cellHumansPhysical and Theoretical ChemistryeducationMolecular Biologylcsh:QH301-705.5Spectroscopyeducation.field_of_studyCytokine-induced killer cellsbiologyCytokine-induced killer cellbusiness.industryOrganic ChemistryGeneral MedicineComputer Science ApplicationsClinical trialKiller Cells Naturalmedicine.anatomical_structureCytokine-induced killer celllcsh:Biology (General)lcsh:QD1-999Cancer cellbiology.proteinCancer researchbusiness
researchProduct

The hemolysin-producer coelomocytes in Holothuria polii

1988

Using sodium metrizoate discontinuous gradients, two hemolysin-producer amebocyte populations have been separated from total circulating Holothuria polii coelomocytes. The amebocytes of population 1 are responsible for the production of the calcium-dependent and temperature-labile hemolysin, whereas those of population 2 produce the calcium-independent and temperature-stable one. The intracytoplasmic hemolysins were evidenced also by immunofluorescence. Petaloid and filipodial amebocytes were the only positive cell types.

Cytotoxicity ImmunologicAmebocyteeducation.field_of_studymedicine.diagnostic_testbiologyImmunologyPopulationTemperatureFluorescent Antibody TechniqueHemolysinImmunofluorescencebiology.organism_classificationMicrobiologyHemolysin ProteinsmedicineAnimalsHolothuriaeducationCoelomocyteEchinodermataDevelopmental BiologyDevelopmental & Comparative Immunology
researchProduct

Consequences of antigen self-presentation by tumor-specific cytotoxic T cells.

2000

Abstract CDS-positive cytotoxic T cells (CTL) recognize antigenic peptides in combination with major histocompatibility complex (MHC) class I molecules on the surface of syngeneic antigen presenting cells (APC). In the present paper we show that cells from tumor antigen-specific CTL clones present their cognate antigenic peptide to other CTL from the same clone. Inter-CTL peptide presentation resulted in activation of the cells of one CTL clone to MHC-unrestricted lysis of bystander cells. In contrast to the behaviour of this clone, another CTL clone did not lyse bystander cells after incubation with the cognate peptide, but was activated to self-destruction. The human herpes virus Epstein-…

Cytotoxicity ImmunologicAntigen PresentationbiologyT cellImmunologyAntigen presentationchemical and pharmacologic phenomenaHematologyMHC restrictionMajor histocompatibility complexMolecular biologyCTL*medicine.anatomical_structureAntigenHLA-A2 Antigenbiology.proteinmedicineTumor Cells CulturedImmunology and AllergyCytotoxic T cellHumansAntigen-presenting cellCell Line TransformedT-Lymphocytes CytotoxicImmunobiology
researchProduct

Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing

2014

Gemcitabine is a chemotherapy agent commonly used in the treatment of non-small cell lung cancer (NSCLC) that has been demonstrated to induce apoptosis in NSCLC cells by increasing functionally active Fas expression. The aim of this study was to evaluate the Fas/Fas ligand (FasL) system involvement in gemcitabine-induced lung cancer cell killing. NSCLC H292 cells were cultured in the presence or absence of gemcitabine. FasL mRNA and protein were evaluated by real-time PCR, and by Western blot and flow cytometry, respectively. Apoptosis of FasL-expressing cells was evaluated by flow cytometry, and caspase-8 and caspase-3 activation by Western blot and a colorimetric assay. Cytotoxicity of ly…

Cytotoxicity ImmunologicAntimetabolites AntineoplasticFas Ligand ProteinLung NeoplasmsImmunologychemical and pharmacologic phenomenaApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioDeoxycytidineFas ligandFlow cytometryCarcinoma Non-Small-Cell LungCell Line TumormedicineImmunology and AllergyCytotoxic T cellHumansfas ReceptorLung cancerAutocrine signallingKiller Cells Lymphokine-ActivatedCaspase 8Lymphokine-activated killer cellmedicine.diagnostic_testChemistryCaspase 3Original Articlesmedicine.diseaseMolecular biologyGemcitabineGemcitabineApoptosisapoptosis cytotoxic lymphocytes non-small cell lung cancermedicine.drug
researchProduct

Cytotoxic effects of antibodies to proteinase 3 (C-ANCA) on human endothelial cells.

1994

SUMMARY Autoantibodies directed against cytoplasmic antigens of neutrophils (ANCA), especially those with specificity for proteinase 3 (PR-3) and myeloperoxidase, are valuable markers for differential diagnosis and monitoring of disease activity in Wegener's granulomatosis (WG) and other vasculitides. Till now, several concepts concerning a direct role of antibodies against PR-3 in the pathogenesis of WG have been discussed. Recently we were able to show that these antibodies recognize PR-3 translocated into the membrane of human endothelial cells. The aim of this study was to investigate putative cytotoxic effects of antibodies to PR-3 on human endothelial cells. Antibodies were obtained b…

Cytotoxicity ImmunologicC-ANCAEndotheliumMyeloblastinImmunologyAutoantigensChromatography AffinityAntibodies Antineutrophil CytoplasmicAntigenProteinase 3medicineImmunology and AllergyCytotoxic T cellHumansLupus Erythematosus SystemicCells CulturedAutoantibodiesMixed Connective Tissue DiseasebiologySerine EndopeptidasesAntibody-Dependent Cell CytotoxicityGranulomatosis with PolyangiitisEndothelial stem cellmedicine.anatomical_structureSjogren's SyndromeMyeloperoxidaseImmunologybiology.proteinEndothelium VascularAntibodyResearch ArticleClinical and experimental immunology
researchProduct

T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice

2015

Background & Aims Cancer therapies are being developed based on our ability to direct T cells against tumor antigens. Glypican-3 (GPC3) is expressed by 75% of all hepatocellular carcinomas (HCC), but not in healthy liver tissue or other organs. We aimed to generate T cells with GPC3-specific receptors that recognize HCC and used them to eliminate GPC3-expressing xenograft tumors grown from human HCC cells in mice. Methods We used mass spectrometry to obtain a comprehensive peptidome from GPC3-expressing hepatoma cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identify immunodominant peptides. To circumvent GPC3 tolerance resulting from feta…

Cytotoxicity ImmunologicCancer Immunotherapy ; Immune Response ; Liver Cancer ; Tumor-associated AntigensCarcinoma HepatocellularTime FactorsCell SurvivalMice SCIDCD8-Positive T-LymphocytesBiologyLymphocyte ActivationTransfectionImmunotherapy AdoptiveInterferon-gammaInterleukin 21GlypicansHLA-A2 AntigenAnimalsHumansCytotoxic T cellIL-2 receptorAntigen-presenting cellInterleukin 3HepatologyImmunodominant EpitopesZAP70Liver NeoplasmsGastroenterologyDendritic CellsHep G2 CellsNatural killer T cellXenograft Model Antitumor AssaysMolecular biologyCoculture TechniquesGenes T-Cell ReceptorInterleukin 12FemaleGenetic Engineering
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-…

2000

The HER-2/neu oncoprotein, a 185 kDa membrane-associated tyrosine kinase with extensive homology to the epidermal growth factor receptor (EGF-R), is overexpressed in breast and ovarian carcinomas. Its overexpression is closely associated with poor prognosis in the course of disease. Here we demonstrate HER-2/neu overexpression in both established cell lines and biopsy material obtained from renal epithelial tumors. Immunohistochemical analysis of human kidney tumor lesions using 2 HER-2/neu-specific antibodies revealed HER-2/neu expression in more than 40% of primary epithelial renal tumors and more than 30% of primary renal cell carcinoma (RCC) specimens. A distinctive HER-2/neu expression…

Cytotoxicity ImmunologicCancer ResearchCellular immunityPathologymedicine.medical_specialtyReceptor ErbB-2BiologyEpitopeEpitopesAntigenRenal cell carcinomaAntigens NeoplasmHLA-A2 AntigenmedicineCytotoxic T cellHumansRNA MessengerRNA NeoplasmCarcinoma Renal CellNeoplasm StagingDendritic CellsGenes erbB-2medicine.diseaseKidney NeoplasmsPeptide FragmentsNeoplasm ProteinsCTL*OncologyCancer researchbiology.proteinImmunohistochemistryAntibodyT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct